You are here

Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA203436-01A1
Agency Tracking Number: R41CA203436
Amount: $299,998.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 103
Solicitation Number: PA15-270
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-09-13
Award End Date (Contract End Date): 2018-05-31
Small Business Information
Ambler, PA 19002-1859
United States
DUNS: 966735149
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (215) 746-2805
Business Contact
Phone: (215) 589-6356
Research Institution

Specific targeting of the Ataxia Telangiectasia and Rad related kinase ATR represents an emerging
strategy to treat a broad spectrum of cancers most notably those that currently lack effective treatments
Suppression of ATR selectively kills cells subjected to oncogenic stress alternative lengthening of telomeres
ALT or loss of double strand break DSB repair mechanisms ATM BRCA or BRCA deficiency Indeed
levels of ATR suppression that eliminate such cancers do so with minimal toxicity to tissues under normal
proliferative control including those that are the most sensitive to traditional chemotherapeutics such as the
bone marrow and intestine Therefore ATR inhibitors provide a new and effective treatment for cancer one
that causes fewer side effects than conventional chemotherapies
Atrin Pharmaceuticals has synthesized a novel series of small molecules that inhibit ATR at low nanomolar
concentrations in cultured cells These compounds have the highest known potency for inhibiting ATR and
maintain andgt fold lower in vivo activity towards other kinases of the same family ATM DNA PKcs and
mTOR which are substantially off targeted by all previously reported ATR inhibitors Herein we propose to
complete our preliminary evaluation of Atrin s ATR inhibitor series by further defining the mechanism of
action and enhancing the pharmacologic properties of the ATRN series and exploring the ability of the
ATRN series to kill cancers in combination with conventional therapies The ultimate goal of this proposed
research is to produce a uniquely specific small molecule inhibitor of ATR that can be applied in the clinic PROJECT NARRATIVE
By inhibiting the activity of the ATR protein kinase it is possible to selectively kill cancer cells with limited
side toxicity to healthy tissues It is therefore expected that our novel ATR inhibitors will be able to treat a broad
spectrum of cancers with fewer adverse effects than conventional chemotherapeutic treatments Herein we
propose to test this hypothesis and produce one or more compounds for clinical application

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government